“Bispecific Antibodies and
Antibody-drug Conjugates”
Friday 16 October 2015
Ablynx, Ghent, Belgium
| 8:30-9:00 | Coffee |
| 9:00-9:10 | Welcome |
| Morning session: Lectures | |
| 9:10-9:55 | Non-clinical considerations in the development of bispecific antibodies in inflammatory diseases B. Schlereth, Covagen, Germany |
| 9:55-10:40 | Nonclinical assessment of Bispecific T cell-engaging Antibodies (BiTE®) and their transition into the clinic for anti-cancer therapy B Rattel, Amgen/Micromet, Germany |
| 10:40-11:10 | Coffee break |
| 11:10-11:40 | Bioanalytical considerations for bispecific antibodies and antibody-drug conjugates TBD |
| 11:40-12:25 | Nonclinical safety perspective on the development of Antibody-Drug-Conjugates D van den Dobbelsteen, Synthon, The Netherlands |
| 12:25-13:30 | Lunch and networking |
| Afternoon session: Case studies analysis | |
| 13:30-13:45 | Introduction to breakout sessions |
| 13:45-14:50 | Breakout sessions |
| 14:50-15:05 | Coffee break |
| 15:05-16:20 | Case study reporting and discussion |
| 16:20-16:30 | Concluding remarks |
Organizing Committee:
Judith Baumeister (Ablynx), Micaela Damsten, Frédérique Delannois and Lawrence Segal (GSK Vaccines), Miek Desmidt, Ad Knaapen and Ilham Smyej (Johnson & Johnson), Annick Cauvin and Miranda Cornet (UCB Pharma)
To download the program, the itinerary or the list of recommended hotels, please use the attachments below:
Programme Workshop Safety Assessment Biopharm 2015
Address Ablynx & recommended hotels Gent